Document Detail


A reappraisal of quinolone tolerability. The experience of their musculoskeletal adverse effects.
MedLine Citation:
PMID:  8652078     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The experience of the rheumatological adverse effects of fluoroquinolones should be helpful for both toxicologists and epidemiologists. In the case of fluoroquinolone-related arthropathy, the paediatric clinical experience seems to support the possible use of newer derivatives like ciprofloxacin in children who really need it. This therapeutic attitude is still contradictory to the labelling of fluoroquinolones. Inversely, there has been an important time-lag between the first reports of fluoroquinolone-related tendinopathies and the official recognition of this unusual toxic phenomenon. This delay, along with the widespread use of fluoroquinolones, makes it difficult to return to more reasonable prescribing guidelines for these very useful and effective anti-microbial compounds. The reasons why potentially serious adverse effects of fluoroquinolones were not anticipated before their commercialisation may be related to the lack of adequate in vitro and in vivo models, and the unexpectedness of the events. When it occurs, fluoroquinolone-induced arthropathy is most frequently benign, and heals without sequelae. The prognosis is not so favourable in the case of fluoroquinolone-related tendinopathy, which carries an important risk of immediate or secondary tendon rupture. Increasingly, fluoroquinolones are being prescribed for benign infections of the urinary or bronchopulmonary tracts. Sometimes, they are even used for antimicrobial prophylaxis before surgical or endoscopic procedures. We believe that for any prescription, the risk/benefit ratio of the fluoroquinolones should be carefully considered, since better tolerated, less expensive drugs can usually be prescribed. Clear information dedicated both to physicians and patients regarding the cautions for use and possible adverse effects of fluoroquinolones would help reduce the risk and severity of adverse reactions. This is especially important for phototoxicity, tendinopathy and cardiovascular adverse effects. As underlined by Ball and Tillotson in this issue, the future clinical use of the fluoroquinolones will be determined by the balance between the antibacterial efficacy and adverse effects of these agents. The adverse reactions affecting the musculoskeletal system provide a good example of this dilemma. Given the absence of an adequate model of tendinopathy and the poor predictivity of animal manifestations in arthropathy and cartilage lesions in humans, careful monitoring of patients during phase II and III trials and, more importantly, long term pharmacovigilance during the postmarketing period, are still strongly warranted.
Authors:
G Hayem; C Carbon
Related Documents :
21453248 - Microneedles and their applications.
115448 - Kanamycin in the treatment of penicillinase-producing gonococcai infections.
15606448 - National differences in publishing papers on adverse drug reactions.
1291478 - Background noise in healthy volunteers--a consideration in adverse drug reaction studies.
3474108 - Effects of anti-tuberculosis drugs on the production of prostaglandin e2 and on mononuc...
23235958 - A prodrug nanoassembly entrapping drugs as a tumor-targeted delivery system.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Drug safety     Volume:  13     ISSN:  0114-5916     ISO Abbreviation:  Drug Saf     Publication Date:  1995 Dec 
Date Detail:
Created Date:  1996-07-30     Completed Date:  1996-07-30     Revised Date:  2014-11-17    
Medline Journal Info:
Nlm Unique ID:  9002928     Medline TA:  Drug Saf     Country:  NEW ZEALAND    
Other Details:
Languages:  eng     Pagination:  338-42     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Age Factors
Anti-Infective Agents / adverse effects*
Arthropathy, Neurogenic / chemically induced*
Fluoroquinolones
Muscular Diseases / classification
Tendons / drug effects
Chemical
Reg. No./Substance:
0/Anti-Infective Agents; 0/Fluoroquinolones

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Safety implications of transferring the oral contraceptive from prescription-only to over-the-counte...
Next Document:  Tolerability of fluoroquinolone antibiotics. Past, present and future.